GP2013 in Japanese Patients With CD20 Positive Low Tumor Burden Indolent B-cell Non-Hodgkin's Lymphoma

Exclusion Criteria

• •Patient who has received radiotherapy within the last 28 days prior to administration, or are not recovered from previous radiotherapy.
• •Patient who has received immunotherapy, chemotherapy, antibodies and experimental treatment within the last 28 days prior to administration, or are not recovered from previous therapy.
• •Patient who has mAb therapy other than rituximab as prior line of therapy.
• •Patient with evidence of any uncontrolled, acute or chronic active infection (viral, bacterial or fungal).
• •Patient with any other malignancy within 5 years prior to date of screening, with the exception of adequately treated in situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or nonmelanomatous skin cancer.